Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Products under Development by Stage of Development | 7 | 1 |
| Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Products under Development by Therapy Area | 8 | 1 |
| Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Products under Development by Indication | 9 | 1 |
| Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Products under Development by Companies | 12 | 2 |
| Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Therapeutics Assessment | 14 | 5 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 2 |
| Assessment by Molecule Type | 18 | 1 |
| Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Companies Involved in Therapeutics Development | 19 | 2 |
| Nivalis Therapeutics, Inc. | 19 | 1 |
| Saje Pharma, LLC | 20 | 1 |
| Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Drug Profiles | 21 | 9 |
| N-91115 Drug Profile | 21 | 3 |
| N-91138 Drug Profile | 24 | 1 |
| N-91169 Drug Profile | 25 | 1 |
| SPL-227.1 Drug Profile | 26 | 1 |
| SPL-334.1 Drug Profile | 27 | 1 |
| SPL-875.1 Drug Profile | 28 | 1 |
| SPL-891.1 Drug Profile | 29 | 1 |
| Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Dormant Projects | 30 | 2 |
| Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Discontinued Products | 32 | 1 |
| Formaldehyde Dehydrogenase (S-Nitrosoglutathione Reductase or NAD-Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) Featured News &Press Releases | 33 | 8 |
| May 16, 2016: Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis | 33 | 1 |
| Apr 05, 2016: Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis | 33 | 1 |
| Mar 07, 2016: Nivalis Therapeutics Expands N91115 Clinical Development Program in Cystic Fibrosis | 34 | 1 |
| Mar 01, 2016: Nivalis Therapeutics Announces Appointment of Paul Sekhri to Its Board of Directors | 35 | 1 |
| Feb 29, 2016: Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results | 35 | 1 |
| Feb 18, 2016: Nivalis Therapeutics Announces FDA Fast Track Designation for N91115 in Patients With Cystic Fibrosis | 36 | 1 |
| Jan 15, 2016: Nivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis | 37 | 1 |
| Dec 01, 2015: Nivalis Therapeutics Announces First Patient Dosed in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis | 37 | 1 |
| Oct 07, 2015: Nivalis Therapeutics Announces Positive Phase 1b Results for N91115 in Patients With Cystic Fibrosis and Plans to Initiate Phase 2 Trial | 38 | 1 |
| Mar 14, 2014: N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy | 39 | 1 |
| Mar 12, 2014: N30 Announces Start of Oral Dosing of N91115 in a Phase 1 Clinical Trial | 39 | 2 |
| Appendix | 41 | 2 |
| Methodology | 41 | 1 |
| Coverage | 41 | 1 |
| Secondary Research | 41 | 1 |
| Primary Research | 41 | 1 |
| Expert Panel Validation | 41 | 1 |
| Contact Us | 41 | 1 |
| Disclaimer | 42 | 1 |